Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) will participate in the 38th Annual Roth Conference in Dana Point, CA, on March 23–24, 2026. CEO James Rolke and CFO Chester S. Zygmont III will attend, and the company will hold a fireside chat on March 24, 2026 at 2:00 p.m. PT.
The fireside chat will be webcast live and later posted in the Investors section at www.RevBiosciences.com. Investors seeking meetings should contact their Roth representative.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Momentum data shows mixed biotech moves: 2 peers up and 2 down, including ELAB at about -4.87% and SLXN near +22.22%. With no strong same-direction skew, REVB’s modest +0.83% move appears more stock-specific against a choppy sector backdrop.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings and update | Positive | -0.8% | Year-end 2025 results, cash runway into Q1 2027, Gemini clinical progress. |
| Jan 26 | Reverse stock split | Negative | -14.8% | 1-for-4 reverse split to address Nasdaq minimum bid listing requirement. |
| Jan 23 | Warrant inducement deal | Negative | -24.4% | Immediate exercise of warrants for ~$11M gross proceeds and new Class J warrants. |
| Jan 21 | FDA pathway agreement | Positive | -10.1% | FDA agreement on single adaptive Phase 2/3 Gemini study in AKI (~300 patients). |
| Jan 14 | Conference data presentation | Positive | -0.6% | PRIME study data on Gemini at critical care nephrology conference in San Diego. |
Recent REVB news, including positive clinical and regulatory updates, has often been followed by negative price reactions, and dilutive or structural actions like splits and warrant deals have also coincided with selling.
Over the last few months, REVB has combined financing, structural actions, and clinical progress. A Jan 23, 2026 warrant inducement generated roughly $11M but saw a sharp selloff. A 1-for-4 reverse split on Jan 28 also drew a negative reaction. In parallel, the company reached an FDA agreement for a single Phase 2/3 Gemini study and reported PRIME data, yet those positives were met with modest declines. Today’s conference fireside chat fits into this ongoing visibility and outreach effort.
Regulatory & Risk Context
An effective Form S-3/A shelf, tied to Class I warrants at $2.20 per share, could bring up to $28,743,000 in cash if fully exercised. The company itself is not selling shares under this prospectus, but warrant exercises would increase the share count over time.
Market Pulse Summary
This announcement centers on REVB’s participation in a fireside chat at the 38th Annual Roth Conference, providing another forum to discuss its Gemini program and recent financings. Historically, key milestones such as the FDA’s Phase 2/3 pathway agreement and warrant inducement deals have been followed by mixed share reactions. Investors may watch how management frames clinical timelines, capital needs, and the existing S-3/A warrant shelf when evaluating future developments.
AI-generated analysis. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, announced today that James Rolke, Revelation's Chief Executive Officer, and Chester S. Zygmont, III, Revelation's Chief Financial Officer, will be attending the 38th Annual Roth Conference, in Dana Point, CA, on Monday and Tuesday March 23rd and 24th. On Tuesday, March 24, 2026, at 2:00 p.m. PT, the Company will participate in a fireside chat.
The fireside chat will be webcast live here and available on our Investors section of the Revelation Biosciences website, www.RevBiosciences.com, after the meeting.
Investors who wish to schedule a meeting with Revelation's management during the conference should contact their Roth representative.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
For more information, please visit www.RevBiosciences.com.
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Revelation Biosciences (REVB) present at the 38th Annual Roth Conference?
How can investors watch the Revelation Biosciences (REVB) fireside chat on March 24, 2026?
Who from Revelation Biosciences (REVB) will attend the Roth Conference in March 2026?
Can investors schedule one-on-one meetings with Revelation Biosciences (REVB) at the Roth Conference?
Where will the recording of Revelation Biosciences (REVB) fireside chat be available after the Roth Conference?
What time is the Revelation Biosciences (REVB) fireside chat at the 38th Annual Roth Conference on March 24, 2026?
